Proteome Sciences (PRM) AI Stock Analysis

• Market Cap: £9.00M
• Dividend Yield: N/A
• Average Volume (3M): 152.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.34
• Revenue Growth: -2.80%
• EPS Growth: -38.55%
• Country: UK
• Employees: 36
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 295,182,040
• 10 Day Avg. Volume: 212,826
• 30 Day Avg. Volume: 152,952
• PEG Ratio: <0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: <0.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: 3.00p ▼(-1.64%Downside)

The overall stock score is primarily impacted by Proteome Sciences' severe financial challenges, highlighted by negative earnings and declining revenues. While technical indicators warn of bearish momentum, positive corporate events suggest some future growth potential. However, the financial instability remains a critical concern.

Proteome Sciences Business Overview & Revenue Model

Company Description

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

How the Company Makes Money

Proteome Sciences generates revenue through a mix of service contracts and licensing agreements. The company offers contract research services in proteomics, leveraging mass spectrometry technology to support pharmaceutical companies in drug discovery and development. This involves providing detailed protein analysis and biomarkers that help in understanding disease mechanisms and treatment efficacy. Additionally, Proteome Sciences licenses its proprietary biomarker technologies and assays to biotech and pharmaceutical companies, which contributes to its revenue streams. The company's earnings are also supported by strategic partnerships and collaborations within the life sciences industry, enabling it to expand its service offerings and reach.

Proteome Sciences Financial Statement Overview

Summary

Proteome Sciences is facing substantial financial challenges, with declining revenues, negative profitability, and high debt levels indicating significant business risks. Negative equity and cash flow issues further exacerbate the company's financial instability.

Income Statement

The company has experienced declining revenue with a decrease from 5.03 million to 4.89 million over the last year, indicating a negative revenue growth rate. The negative EBIT and net income margins highlight ongoing operational challenges with profitability. These factors indicate financial instability in the income statement.

Balance Sheet

The company has a negative stockholders' equity, indicating that liabilities exceed assets, which is a significant concern. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt level suggests potential solvency issues. This balance sheet position suggests high financial risk.

Cash Flow

Operating cash flow is negative, and free cash flow has worsened, indicating cash flow difficulties. The free cash flow to net income ratio is negative, reflecting challenges in generating cash relative to net income. These factors demonstrate weak cash flow management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.89M	5.03M	23.74B	22.59B	16.95B
Gross Profit	670.00K	1.65M	23.73B	22.59B	16.94B
EBITDA	-1.51M	-1.14M	1.83M	625.00K	714.00K
Net Income	-3.41M	-2.44M	1.32M	72.00K	295.00K
Balance Sheet
Total Assets	9.21M	11.46M	1.51T	1.38T	1.35T
Cash, Cash Equivalents and Short-Term Investments	1.13M	2.03M	252.89B	240.31B	193.69B
Total Debt	14.52M	13.47M	139.92B	138.58B	120.95B
Total Liabilities	15.72M	14.52M	1.44T	1.31T	1.28T
Stockholders Equity	-6.52M	-3.07M	68.29B	69.05B	65.80B
Cash Flow
Free Cash Flow	-1.05M	-718.00K	2.14B	8.80B	-9.07B
Operating Cash Flow	-826.00K	-481.00K	3.88B	10.52B	-7.74B
Investing Cash Flow	-224.00K	-424.00K	-21.67B	4.27B	-18.38B
Financing Cash Flow	151.00K	-1.06M	27.05B	38.50B	67.98B

Proteome Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Negative. The current price of 3.05 is below the 20-day moving average (MA) of 3.19, below the 50-day MA of 3.17, and below the 200-day MA of 3.39, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 42.13 is Neutral, neither overbought nor oversold. The STOCH value of 38.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PRM.

Proteome Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABDX	66 Neutral	£13.55M	―	-62.83%	―	27.60%	1.35%
Sector *	65 Neutral	¥345.58B	10.59	-2.88%	2.65%	11.80%	-7.09%
GDR	55 Neutral	£8.75M	―	-321.90%	―	125.37%	22.47%
IXI	55 Neutral	£9.41M	―	-13.85%	―	7.27%	39.64%
PRM	44 Neutral	£9.00M	―		―	-2.80%	-38.55%
OBD	42 Neutral	£7.24M	―	-222.16%	―	24.71%	38.28%
GENI		£6.45M	―	-367.05%	―	―	―

Proteome Sciences Corporate Events

Proteome Sciences Announces Successful AGM Resolutions

Proteome Sciences announced that all resolutions were passed at their Annual General Meeting, indicating strong shareholder support and a stable governance structure. This outcome reinforces the company’s strategic direction and could positively impact its market position in the proteomics industry, benefiting stakeholders by ensuring continued focus on innovative drug discovery and biomarker identification services.

Proteome Sciences Sees Strong Recovery and Growth Prospects

At its Annual General Meeting, Proteome Sciences announced a continued recovery in the pharmaceutical and biotech markets, with a strong pipeline of orders extending into 2026. The company is progressing with licensing discussions for new DXT tags and has completed its first commercial single cell proteomics project. The increased demand has led to full capacity utilization at their Frankfurt site, positioning the company for substantial future revenue growth.

Proteome Sciences Reports 2024 Financial Results Amid Market Recovery

Proteome Sciences reported its final results for 2024, highlighting a total revenue of £4.89 million, a slight decrease from the previous year. Despite a challenging start due to the global downturn in biotech and pharma markets, the company saw a strong recovery in the second half of 2024, driven by increased customer orders and the launch of new products like TMTpro 35 plex tags. The company secured significant contracts, including a GCLP contract with a US biopharmaceutical company, and expanded its service offerings with data-independent acquisition and single-cell proteomics. Looking forward, Proteome Sciences anticipates substantial growth, with a robust order pipeline extending into 2026, supported by investments in new laboratory facilities and equipment.

Proteome Sciences to Announce 2024 Financial Results and Host Investor Presentation

Proteome Sciences announced that it will release its financial results for the year ending 31 December 2024 on 10 April 2025. The company will host a live presentation on 11 April 2025, led by Executive Chairman Christopher Pearce and Chief Scientific Officer Dr. Ian Pike, to discuss the results and outlook for 2025. This presentation is accessible to all existing and potential shareholders, allowing them to submit questions in advance or during the event. This announcement is significant as it provides stakeholders with insights into the company’s performance and future plans, potentially impacting investor confidence and market positioning.